The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Reacquisition of RAI uptake in RAI-refractory metastatic thyroid cancers by pretreatment with the MEK inhibitor selumetinib.
Alan Loh Ho
Consultant or Advisory Role - AstraZeneca
Research Funding - AstraZeneca
Rebecca Leboeuf
No relevant relationships to disclose
Ravinder K. Grewal
No relevant relationships to disclose
Eric Jeffrey Sherman
No relevant relationships to disclose
Desiree Deandreis
No relevant relationships to disclose
Keith S. Pentlow
No relevant relationships to disclose
Robert Michael Tuttle
Consultant or Advisory Role - AstraZeneca (U)
Matthew G. Fury
No relevant relationships to disclose
Julio Cezar M. Ricarte-Filho
No relevant relationships to disclose
David G. Pfister
Research Funding - AstraZeneca
Steven M. Larson
Consultant or Advisory Role - ACR Image Metrix; Cougar Biotechnology; ImaginAb; Millennium; Perceptive Informatics; Senior Scientific LLC
James A. Fagin
No relevant relationships to disclose